ACADIA Pharmaceuticals Inc (ACAD) reports a 32% annual revenue increase, driven by strong sales of DAYBUE and NUPLAZID, while expanding its pipeline and preparing for European market entry.

Objective: To review clinical trials and reports describing the efficacy and safety of atypical antipsychotics (olanzapine, ziprasidone, quetiapine, aripiprazole) in the treatment of autistic or ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

President Donald Trump and HHS Secretary Robert F. Kennedy Jr. said they will be studying the "threat" to children posed by ...

Talk about a heavy dose. While the bulk of news coverage is focused on GLP-1 drugs like Ozempic that cause weight loss, ...

Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.

Second-generation (or atypical antipsychotics) — they work on serotonin and dopamine. Different antipsychotics vary in their side effects, and some people may experience certain side effects ...

such as emraclidine and KarXT (see the discussion on Karuna below), have a very different mechanism of action compared with the standard-of-care atypical antipsychotics like Vraylar. Additionally ...

Additionally, there are currently six atypical, or second-generation, antipsychotics that are FDA-approved for use in children and adolescents. They are generally considered safe but come with ...

Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...